-
Rethinking “Very High-Risk”: Prof. Karim Fizazi on PEACE-2 Results and the Evolution of Prostate Cancer Risk Stratification
During a recent major international oncology congress, Professor Karim Fizazi from the University of Paris-Saclay (Gustave Roussy) presented the first results of the Phase III PEACE-2 trial. This study evaluated whether the addition of cabazitaxel and/or pelvic radiotherapy to the standard of care—androgen deprivation therapy (ADT) combined with prostate radiation—improves outcomes in patients with very…
-
Combination Therapy Breakthrough Exceeds 5 Years OS! BRCAaway Trial Establishes the Core Role of Abiraterone + Olaparib in BRCA-Mutated mCRPC
At a recent major oncology academic conference, Professor Maha Hussain from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University in Chicago presented the latest efficacy and overall survival (OS) data from the BRCAaway trial (Abstract 16). This Phase II clinical trial thoroughly investigated the definitive efficacy and safety profile of abiraterone combined with…
-
Dr. Martin Gleave Deciphers GUNS Study: Triplet Therapy Significantly Increases MRD Rates in Genomically Aggressive Prostate Cancer
At the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium (GU ASCO), Dr. Martin Gleave from the University of British Columbia presented the latest data from the GUNS study (Genomic Umbrella Neoadjuvant Study). The presentation focused on the pathological responses of high-risk prostate cancer (PCa) patients with aggressive genomic alterations treated with neoadjuvant androgen…
-
Balancing Efficacy and Well-being: PRO Dynamics and Skeletal Safety in the Phase 3 PSMAddition Trial for mHSPC
At a recent international oncology symposium, Michael Morris, MD, from Memorial Sloan Kettering Cancer Center (MSKCC), delivered an in-depth academic report on Abstract #18. The presentation focused on the latest data regarding health-related quality of life (HRQoL), pain, and symptomatic skeletal events (SSE) from the Phase 3 PSMAddition study. This trial evaluates the efficacy and…
-
EBRT vs. Brachytherapy Boost in Localized Prostate Cancer: In-Depth Analysis of 15-Year OS and PCSM Data from the ASCENDE-RT Trial
At a recent international oncology conference, Professor Scott Tyldesley from Vancouver, Canada, delivered an oral presentation on behalf of Professor Jim Morris, sharing the 15-year long-term survival analysis of the ASCENDE-RT trial (Abstract No. 306). This study compared the long-term overall survival (OS) and prostate cancer-specific mortality (PCSM) of an external beam radiotherapy (EBRT) boost…
-
Neoplasia | Teams Led by Jianxiang Wang and Shaowei Qiu Reveal Prognostic Heterogeneity in FLT3-ITD–Mutated AML: Clonal Origin and 13q UPD as Key Drivers
Acute myeloid leukemia (AML) is a highly heterogeneous hematologic malignancy. Approximately 20–30% of AML patients harbor FLT3 internal tandem duplication (FLT3-ITD) mutations. FLT3-ITD is a major driver mutation in AML and typically arises as a late genetic event during leukemogenesis, often coexisting with mutations in NPM1, DNMT3A, WT1, and others. Although FLT3-ITD is generally associated…
-
Professor Wang Sanbin: Advancing Integrative Rehabilitation and Translating Cutting-Edge Therapies in Lymphoma Care
From November 6 to 9, 2025, the China Conference on Holistic and Integrative Oncology (CCHIO 2025) was grandly convened in Kunming. As one of China’s largest and most influential oncology meetings, the conference gathered many leading national and international oncology experts to explore the latest advances and future directions in cancer prevention and treatment through…
-
Professor YanminZhao: A New Management Framework for TP53 Mutations — From MRD Monitoring to Emerging Treatment Strategies | 2025 International Cell & Immunotherapy Congress
mmunotherapy field, enhance communication on key scientific issues, share the latest clinical advances, and foster global collaboration and translational progress, the 2025 International Cell & Immunotherapy Congress (CTI 2025)—jointly organized by Zhejiang University, the International Academy for Clinical Hematology (IACH), Zhejiang Immunological Society and Zhejiang Anti-Cancer Association—was held on November 13–16, 2025 in Hangzhou, China,…
Connecting Medical Expertise through Media